Solstein Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Solstein Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$925K	Buy	5,848 +1,983	+51%	+$268K	0.32%	67
2026 Q1	$494K	Buy	3,865 +1,964	+103%	+$245K	0.2%	83
2025 Q4	$232K	Buy	+1,901	New	+$218K	0.09%	120
2022 Q3	–	Sell	-860	Closed	-$64K	–	347
2022 Q2	$64K	Hold	860	–	–	0.05%	165
2022 Q1	$77K	Hold	860	–	–	0.05%	165
2021 Q4	$96K	Hold	860	–	–	0.06%	166
2021 Q3	$108K	Hold	860	–	–	0.06%	170
2021 Q2	$116K	Hold	860	–	–	0.14%	149
2021 Q1	$117K	Buy	+860	New	+$129K	0.16%	143

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Solstein Capital's XBI Position: Q2 2026 in Review

Solstein Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 51% in Q2 2026, buying an estimated $268K and bringing the position to 5,848 shares worth $925K. The position accounts for 0.32% of the portfolio, ranked #67.

Solstein Capital first reported a position in XBI in Q1 2021 and has held it in 9 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Solstein Capital held 5,848 shares of State Street SPDR S&P Biotech ETF worth $925K as of Q2 2026.
Solstein Capital bought 1,983 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $268K.
State Street SPDR S&P Biotech ETF made up 0.32% of Solstein Capital's portfolio in Q2 2026, its #67 holding.
Solstein Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and has held it in 9 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Solstein Capital's 13F filing for Q2 2026, filed 13 Aug 2026.